Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.
about
Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulationNVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer modelsThe ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferationContribution of the Type II Chaperonin, TRiC/CCT, to OncogenesisHER2 expression beyond breast cancer: therapeutic implications for gynecologic malignanciesNAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinonesHsp90 inhibition decreases mitochondrial protein turnover.MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancerPersonalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimensPhotodynamic Therapy with Hypericin Improved by Targeting HSP90 Associated Proteins.Stromal hyaluronan interaction with epithelial CD44 variants promotes prostate cancer invasiveness by augmenting expression and function of hepatocyte growth factor and androgen receptorThe nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression.Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growthHER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.Cytokeratin19 induced by HER2/ERK binds and stabilizes HER2 on cell membranes.SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.Heat shock proteins as emerging therapeutic targets.Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer.The survival kinases Akt and Pim as potential pharmacological targets.Heat shock proteins: essential proteins for apoptosis regulation.The ERBB3 receptor in cancer and cancer gene therapyMechanisms of ErbB receptor negative regulation and relevance in cancer.Hsp90 inhibitors promote p53-dependent apoptosis through PUMA and Bax.Apoptosis versus cell differentiation: role of heat shock proteins HSP90, HSP70 and HSP27Enhanced Human Epidermal Growth Factor Receptor 2 Degradation in Breast Cancer Cells by Lysosome-Targeting Gold Nanoconstructs.HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer.A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors.Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis.Identification of mixed lineage leukemia 1(MLL1) protein as a coactivator of heat shock factor 1(HSF1) protein in response to heat shock protein 90 (HSP90) inhibition.Targeting HSF1 sensitizes cancer cells to HSP90 inhibition.BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma.Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.The heat shock protein antagonist 17-AAG potentiates the activity of enzastaurin against malignant human glioma cells.Optimal classes of chemotherapeutic agents sensitized by specific small-molecule inhibitors of akt in vitro and in vivoCopolymer micelles function as pH-responsive nanocarriers to enhance the cytotoxicity of a HER2 aptamer in HER2-positive breast cancer cells.FBW7-Dependent Mcl-1 Degradation Mediates the Anticancer Effect of Hsp90 Inhibitors.
P2860
Q21195216-8D93DA57-908B-4B85-9105-CC48DD8179BBQ21195221-B44BF57A-F0E7-4BD8-A646-D3D4BF10EC43Q24678674-FE63056A-B0ED-475B-875A-D4341A1C92E6Q26777412-440C167A-22AA-4B0F-99CF-C59F77F45B16Q26822730-F52471D0-3BDD-493F-8DDE-30C30DE8A581Q26823209-A98114F4-2E8C-4AAC-9794-23E0FA6C01B3Q33303676-290913D4-7E36-45CE-BD26-D8BBA73F7713Q33443571-4C53BC84-AE0E-454F-97E3-9EF168365B92Q33735413-4F7F10C1-FC0A-4C32-A174-3556C08BB737Q33765280-CD644C9F-8ECE-4693-9255-3CAE753D3312Q33924267-57986C82-2970-413A-8E39-52D162E9B2A7Q34127212-28D4FDBC-31B0-46FA-96BE-AF35A8EF891BQ34669979-AB9070F2-838F-4772-9159-863450CF5ECCQ34974436-BC22551D-42CD-4CC9-9F44-0C188D449012Q35167598-C61DC1BC-2C48-4A81-9538-5502EC62F149Q35469447-4046906C-5561-4D77-A868-7B5929393252Q35545091-BA38175C-6752-491F-8A5B-0A203472B052Q35653820-93DA2CF7-E2BF-44DB-9FA3-7941DC2F91A0Q36274952-C3F96953-DD90-4349-A66E-3015D66B4D97Q37081794-AB83A726-355B-42CF-AD65-236F45D3EF2DQ37135372-0E68F3BC-85E7-48CC-A025-651B20A52DD2Q37244805-6A803337-EA2C-432F-A7AF-13449F57B480Q37296982-64E71615-1FDF-4CC7-8890-C48DD97A59B0Q37375811-764E12B7-C54E-4F19-8DF5-81F9F5446C45Q37613811-03558314-D164-462A-AA2F-863A72CFE619Q37699133-10EDA6FA-6F73-40AA-B391-5C44279296B5Q37718291-D2B6FDF9-6048-4FB5-946E-46388131A847Q38382840-4998935C-A8DF-4B5B-9B86-0AF470DCE088Q38769105-9BFC0087-414A-4624-BD39-4C5DF1016F73Q38994711-889D51C5-05AE-4032-BAAF-392B23E7CC49Q39161041-0CF0CB98-BB5B-4424-AD74-8C181F54E258Q39890111-ABC9C3D0-D809-4481-AD49-5F9DD7C77115Q39953614-90E42CD7-376E-469B-BDDC-73A59C7C3D9CQ39984715-F6548C72-6E06-4750-97DE-7699319E4063Q40343052-47D02360-3582-483B-A2A5-4D008E0A7D47Q49213911-CA33EC16-F856-4245-962C-0B5EBE899292Q50942181-0F9DA9A9-98D1-4DF9-8E1B-A2B326AB400C
P2860
Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Degradation of HER2 by ansamyc ...... -kinase-AKT-dependent pathway.
@en
Degradation of HER2 by ansamyc ...... -kinase-AKT-dependent pathway.
@nl
type
label
Degradation of HER2 by ansamyc ...... -kinase-AKT-dependent pathway.
@en
Degradation of HER2 by ansamyc ...... -kinase-AKT-dependent pathway.
@nl
prefLabel
Degradation of HER2 by ansamyc ...... -kinase-AKT-dependent pathway.
@en
Degradation of HER2 by ansamyc ...... -kinase-AKT-dependent pathway.
@nl
P2093
P1433
P1476
Degradation of HER2 by ansamyc ...... '-kinase-AKT-dependent pathway
@en
P2093
Andrea D Basso
Douglas C Marchion
Neal Rosen
Pamela N Münster
P304
P407
P577
2002-06-01T00:00:00Z